Andrea Ellis is Director at BridgeBio Pharma, Inc. (BBIO). They have made 1 open-market trade across 1 company since 2022, most recently 2026-07-09.
CIK 0001877680
1 open-market purchase totalling $101K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BBIO | 22,579 | $1.5M |
Shares reported on the most recent Form 4, priced at the 2026-07-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BBIO | SELL · 10b5-1 | 2026-07-09 | 2026-07-13 | $84.00 | $1.4M | +0.9% | +1.9% | -20.1% |
| BBIO | SELL · 10b5-1 | 2026-03-04 | 2026-03-06 | $64.87 | $4.2M | +7.6% | +10.9% | +3.3% |
| BBIO | SELL · 10b5-1 | 2025-08-05 | 2025-08-07 | $49.00 | $841K | +7.2% | +19.0% | +37.3% |
| BBIO | SELL · 10b5-1 | 2025-04-14 | 2025-04-16 | $35.00 | $350K | +8.6% | +0.9% | +40.0% |
| BBIO | SELL · 10b5-1 | 2025-04-01 | 2025-04-03 | $34.05 | $2.0M | +2.6% | +14.6% | +28.4% |
| BBIO | BUY | 2022-03-15 | 2022-03-17 | $8.39 | $101K | +0.6% | -5.5% | -37.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.